📈 Jumpstart Signal Watchlist — September 21, 2026

🏢 What they do: Paysign, Inc. is a payments technology company that provides prepaid card programs, integrated payment processing, and digital banking/payment solutions for businesses, healthcare and pharmaceutical clients, and government or consumer payout programs.
- 🎯 Current $12.63 is 11% below 3yr high $14.14 · ⏳ SMA200 $6.96 (current price $12.63 is above) · 💰 Market Cap $713M
- PAYS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 49/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 450% (>20%); Revenue growth 48% (>15%); ROE 26% (>15%); Low LT D/E 0.06 (<1.0).
⏰ Entry (E): 0/20
- 📈 RSI at 52 in healthy mid-range
📢 Sentiment (S): 6/10
- 🗞️ News sentiment is positive (✅×1 ⚪️×4; showing 3 of 5).
✅ Paysign Targets $117M Revenue as Patient-Affordability Business Surges — MarketBeat.
🤖 Paysign's patient-affordability segment grew more than 85% in the first half, with management projecting approximately $60 million in segment revenue for the year. The company forecast total 2026 revenue of $114 million-$117 million, adjusted EBITDA of $35 million-$38 million, and net income of $21.5 million-$23 million, supporting a favorable growth outlook.
⚪️ Paysign EVP, operations Joan Herman sells $716,899 in shares — Investing.com.
🤖 The article reports an executive's disclosed share sales, which are insider transactions rather than a company operating catalyst. It also notes previously reported second-quarter results that beat estimates and a raised full-year outlook.
⚪️ Paysign (NASDAQ:PAYS) EVP Joan Herman Sells 38,900 Shares — MarketBeat.
🤖 This is primarily a report of an EVP sale under a pre-arranged Rule 10b5-1 plan, which is neutral under the requested treatment of ownership disclosures. The article references prior earnings outperformance and a consensus Buy rating but does not report a new analyst action or operating development.
🍭 Bonus (B): 0/10 — Business Services

🏢 What they do: Vir Biotechnology is a clinical-stage biopharmaceutical company that develops medicines for serious infectious diseases and cancer. Its work centers on immune-based therapies, including antibody-based and other platform-driven drug candidates such as programs for hepatitis delta, hepatitis B, and solid tumors.
- 🎯 Current $10.88 is 14% below 3yr high $12.66 · ⏳ SMA200 $8.76 (current price $10.88 is above) · 💰 Market Cap $1.8B
- VIR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 32/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 159% (>20%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×4 ⚪️×1; showing 3 of 5).
✅ Vir Biotechnology stock hits 52-week high at 11.66 USD — Investing.com.
🤖 Vir shares reached a new 52-week high following strong second-quarter results, including a collaboration payment from Astellas, increased cash reserves, and a return to net income. H.C. Wainwright also reiterated a Buy rating and highlighted progress in Vir’s hepatitis D programs.
✅ Vir Biotechnology climbs 9% amid post-earnings uptrend — Seeking Alpha.
🤖 Vir shares rose nearly 9% in a post-earnings move, indicating a favorable market reaction to the company’s recent quarterly results.
⚪️ Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference — Business Wire.
🤖 Vir announced that its CEO would participate in a Morgan Stanley healthcare conference. The announcement provides investor access to management but contained no new results, guidance, partnership, or analyst action.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Ooma, Inc. provides cloud-based VoIP phone systems and unified communications services for businesses and consumers, featuring voice, messaging, video, and AI tools like call transcriptions and answering services. Their primary offerings include Ooma Office for small to mid-sized businesses, Ooma AirDial for POTS line replacement, and Ooma Telo for affordable residential landline service.
- 🎯 Current $22.96 is 2% below 3yr high $23.38 · ⏳ SMA200 $16.31 (current price $22.96 is above) · 💰 Market Cap $629M
- OOMA shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (14.2% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 150% (>20%); Revenue growth 25% (>15%); Low LT D/E 0.46 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ Ooma Introduces StarDial, Bringing Affordable Home Phone Service to Rural and Remote Locations Through Starlink Internet — Business Wire.
🤖 Ooma launched StarDial, a home-phone offering tailored to Starlink users in rural, remote and off-grid areas. The product expands Ooma's addressable market and adds a differentiated connectivity use case.
✅ Ooma (OOMA) Rides A Phone Line Extinction Into Faster Growth — Yahoo Finance.
🤖 The article highlights Ooma's fiscal second-quarter revenue growth of 25% year over year to $83.2 million, supported by migration away from legacy copper phone lines. The reported growth trend is favorable for demand and execution.
✅ Ooma (NYSE:OOMA) Receives Average Rating of "Moderate Buy" from Analysts — MarketBeat.
🤖 The article reports a Moderate Buy analyst consensus, with five Buy ratings and one Hold, plus a $25 average 12-month price target. It also notes B. Riley raised its target to $27, signaling constructive analyst sentiment.
🍭 Bonus (B): 10/10 — Computer Processing & Data Prep (Technology sector)

🏢 What they do: Red Violet, Inc. provides identity intelligence software and data solutions for identity verification, fraud detection and prevention, risk mitigation, investigations, due diligence, customer acquisition, and asset recovery. Its products include idiCORE and FOREWARN.
- 🎯 Current $75.50 is 3% below 3yr high $77.52 · ⏳ SMA200 $53.66 (current price $75.50 is above) · 💰 Market Cap $1.1B
- RDVT shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (13.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 89% (>20%); Revenue growth 23% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ Red Violet (RDVT) Expands FOREWARN Reach Through This Latest Partnership — Yahoo Finance.
🤖 Red Violet subsidiary FOREWARN partnered with the Pacific West Association of REALTORS to provide identity-verification and safety services to more than 10,000 members. The expanded distribution supports customer adoption and visibility for the company’s platform.
✅ Raymond James initiates Red Violet stock coverage with outperform rating — Investing.com.
🤖 Raymond James began coverage with an Outperform rating and a $90 price target. The firm cited Red Violet’s strong fundamentals and growing demand for its identity-intelligence products.
✅ Red Violet (NASDAQ:RDVT) Raised to "Moderate Buy" at Raymond James Financial — MarketBeat.
🤖 Raymond James upgraded Red Violet to Moderate Buy, adding to a favorable analyst consensus. The article also cited quarterly EPS and revenue that exceeded estimates, although the reported institutional ownership activity itself is not treated as a directional catalyst.
🍭 Bonus (B): 10/10 — Prepackaged Software (Technology sector)

🏢 What they do: Five9, Inc. provides cloud contact center software, including its Intelligent CX platform for managing customer interactions across voice and digital channels like chat, email, SMS, and social media. Its products also include AI, automation, analytics, and workforce optimization tools that help businesses run customer service and sales operations.
- 🎯 Current $37.01 is 57% below 3yr high $85.47 · ⏳ SMA200 $21.92 (current price $37.01 is above) · 💰 Market Cap $2.8B
- FIVN shows decent technicals supported by positive sentiment.

💎 Quality (Q): 45/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 300% (>20%); Low LT D/E 0.25 (<1.0); PEG ratio 0.18 (<1.5).
⏰ Entry (E): 7/20
- 🔔 Strong above EMA21 (12.9%)
- 🔔 Strong above EMA50 (21.6%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 65 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ Needham reiterates Buy on Five9 stock, cites AI platform progress — Investing.com.
🤖 Needham maintained a Buy rating and $40 price target after discussions with contact-center technology leaders, citing progress in Five9's AI platform. The target implied meaningful upside from the then-current share price.
✅ Five9 (NASDAQ:FIVN) Shares Up 8.7% After Analyst Upgrade — MarketBeat.
🤖 Cantor Fitzgerald raised its Five9 price target from $34 to $40 while retaining an Overweight rating, coinciding with an 8.7% share-price gain. The article also cited quarterly revenue and adjusted EPS that exceeded expectations.
✅ Cantor Fitzgerald Boosts Five9 (NASDAQ:FIVN) Price Target to $40.00 — MarketBeat.
🤖 Cantor Fitzgerald increased its price objective to $40 from $34 and maintained an Overweight rating, indicating a more favorable analyst valuation outlook. The report also referenced Five9's earnings and revenue beat.
🍭 Bonus (B): 10/10 — Computer Processing & Data Prep (Technology sector)

🏢 What they do: Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes medicines for hard-to-treat cancers. Its main products include CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), and COTELLIC (cobimetinib), and it also advances a pipeline of small molecules and biotherapeutics for cancer treatment.
- 🎯 Current $57.22 is 3% below 3yr high $59.13 · ⏳ SMA200 $48.23 (current price $57.22 is above) · 💰 Market Cap $14.2B
- EXEL shows favorable technicals but negative sentiment warrants caution.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (11.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 26% (>20%); ROE 47% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 54 in healthy mid-range
📢 Sentiment (S): 3/10
- 🗞️ News sentiment is negative (❌×2 ⚪️×3; showing 4 of 5).
❌ Exelixis Shares Fall 3.5% as FDA Extends Zanzalintinib Review by Three Months — Finance Yahoo.
🤖 The FDA extended the review period for zanzalintinib by three months, pushing the decision date to March 3, 2027. A delay in a key regulatory decision is generally negative for the stock because it postpones a potential launch and introduces uncertainty.
❌ Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review ... — Finance Yahoo.
🤖 This article reports that the FDA extended the zanzalintinib review after requesting updated safety and efficacy data. The delay leaves approval unresolved and is negative near term because it pushes back the timeline for a potentially important growth driver.
⚪️ Citizens reiterates Exelixis stock rating on FDA review extension — Investing.com.
🤖 Citizens maintained its Market Outperform rating and $55 price target after Exelixis disclosed an FDA review extension for zanzalintinib. The article also notes Exelixis’ recent Q2 results and lowered full-year revenue guidance, but the rating action itself is not a new operating catalyst.
⚪️ Exelixis at Citigroup summit: building a second growth engine — Investing.com.
🤖 This conference transcript highlights Exelixis’ long-term growth plan around CABOMETYX and zanzalintinib, along with commentary on market share and pipeline breadth. It is mostly a presentation of strategy and expectations rather than a fresh catalyst, so the impact is mixed to neutral.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Hewlett Packard Enterprise (HPE) is an enterprise technology company that provides compute, storage, networking, and software solutions designed for hybrid IT environments and AI infrastructure.
- 🎯 Current $61.75 is 0% below 3yr high $62.09 · ⏳ SMA200 $34.87 (current price $61.75 is above) · 💰 Market Cap $82.0B
- HPE shows decent technicals supported by positive sentiment.

💎 Quality (Q): 49/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 405% (>20%); Revenue growth 34% (>15%); Low LT D/E 0.82 (<1.0); PEG ratio 0.08 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (9.3%)
- 🔔 Strong above EMA50 (16.8%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 61 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (mixed coverage; ✅×4 ❌×1; showing 3 of 5).
✅ Hewlett Packard Enterprise (HPE) Wins Top Zacks Rank, Is It Still a Buy? — Yahoo Finance.
🤖 Analysts raised earnings estimates and assigned HPE a top Zacks Rank following its sector outperformance. Higher earnings expectations are a favorable signal for the stock.
✅ What Does Hewlett Packard Enterprise (HPE) Gain From These Collaborations? — Yahoo Finance.
🤖 HPE expanded its AI-infrastructure partnership with Oracle and signed a digital-modernization project with Tottenham Hotspur. The deployments support demand for HPE's AI, networking and hybrid-cloud offerings.
❌ Hewlett Packard Enterprise Sinks 9% on Downgrade After ... — Yahoo Finance.
🤖 Evercore ISI's downgrade triggered a sharp decline in HPE shares following a substantial year-to-date rally, highlighting valuation and sector-unwind risk. The article notes that the downgrade came despite strong Q3 results and raised guidance.
🍭 Bonus (B): 10/10 — Computer & Office Equipment (Technology sector)